{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.7"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"27.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"37"}],"units":"Participants"}],"description":"This is the percentage of participants who achieved breast conserving surgery out of the intent-to-treat population without inflammatory breast cancer, as these participants received mastectomy irrespective of their response to neoadjuvant (pre-operative) treatment.","groups":[{"description":"5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab and pertuzumab every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG000","title":"T+P Concomitant Anthracycline-based Chemotherapy"},{"description":"FEC every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.","id":"OG001","title":"T+P Sequential Anthracycline-based Chemotherapy"},{"description":"Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.","id":"OG002","title":"T+P Concomitant Non-Anthracycline Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Number of participants analyzed represents the participants with T2-3 tumors for whom mastectomy was planned.","reportingStatus":"POSTED","timeFrame":"At approximately 18 weeks","title":"Efficacy: Percentage of Participants Achieving Breast Conserving Surgery","type":"SECONDARY","unitOfMeasure":"percentage of participants"}